AstraZeneca, Ionis eye U.S. approval after positive trial data https://ift.tt/FuRpQ2t

The drug is designed to reduce the production of transthyretin, or TTR protein. Curbing TTR limits the accumulation of amyloid deposits in peripheral nerves and various organs that causes them to function abnormally.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/BdaWFDy
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.